Medications

Benefits of valoctocogene roxaparvovec persist in hemophilia A

For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated ...

Oncology & Cancer

Experts call for better cancer tests to tailor treatment

Greater use of cancer tests is the key to tailoring use of new treatments for patients more precisely and so increasing their chances of being recommended for use within the NHS, experts say.

page 12 from 40